Skip to main content

Table 1 Endpoints from study investigating single agent celecoxib by Mantovani et al [21]

From: A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

 

Baseline

After treatment

pvalues

TNF-alpha (pg/ml)

36.8 ± 14.1

29.9 ± 12.2

0.007

LBM (Kg)

45.4 ± 6.7

45.8 ± 6.6

< 0.0001

QoL

66.3 ± 19.9

75.3 ± 10.1

0.024

ECOG PS

1.5 ± 0.67

1.2 ± 0.59

0.0023

GPS

1.3 ± 0.77

0.8 ± 0.7

0.0004

Grip strength

20. 8 ± 4.7

24.0 ± 5.5

0.004

  1. TNF-alpha = Tumour Necrosis Factor-alpha, LBM = Lean body mass, QoL = Quality of life, ECOG PS = Eastern Cooperative Oncology Group (ECOG) Performance status, GPS = Glasgow prognostic score. Data are reported as mean ± SD.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us